Immix Biopharma, Inc. (IMMX) Form 424B5 — May 21, 2026
Immix Biopharma (IMMX) is offering 16,778,524 shares of common stock at $8.94 per share, raising gross proceeds of approximately $150 million. The net proceeds of ~$140.65 million will be used to fund the clinical development of its lead CAR-T candidate NXC-201, working capital, and general corporate purposes. The offering coincides with positive clinical updates for NXC-201 in relapsed/refractory AL Amyloidosis, where 95% of the first 20 patients in the Phase 2 NEXICART-2 trial achieved complete response. Management states that the combined cash position of ~$231 million (existing $90.6M plus net proceeds) is sufficient to fund operations into mid-2028.
Key figures
- Net Proceeds
- 140650000
- Cash Position
- 90600000
- Gross Proceeds
- 150000004.56
- Offering Price
- 8.94
- Shares Offered
- 16778524
- Shares Outstanding
- 53012092
- Underwriting Discount
- 9000000.27
- Net Tangible Book Value Per Share
- 1.59
- Post Offering Shares Outstanding
- 69790616
- Pro Forma Net Tangible Book Value Per Share
- 3.35
- Complete Response Rate
- 95%
- Clinical Trial Patients Enrolled
- 45
- Dilution Per Share To New Investors
- 5.59
- Increase In NTBVPer Share To Existing
- 1.55
Price after filing
Close on the filing date to close N calendar days later (from $8.67). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.